Growing up as the only boy among three siblings, Al Barrus is a 43-year-old veteran and communications specialist from New Mexico. After years of witnessing his sisters struggle with painful periods, hormonal turmoil, and skin issues, one of them was eventually diagnosed with polycystic ovary syndrome. He recognized it as a condition specific to women. Anatomical and structural, a female issue confined to a branch of biology he didn’t understand. Then, in silence, he started to wonder if his own body was experiencing something similar.
When he was a teenager, he went bald. He has very little body hair. He battles obesity and mental health issues, has high prolactin levels, and may be insulin resistant. He asked whether there might be a male form of PCOS that hasn’t been identified yet on Reddit, and the answers were quick and contemptuous. “PCOS is a condition that affects ovaries,” a user commented. “Clues in the name,” another person wrote. It was the kind of casual, self-assured certainty that ages poorly when science catches up.
| Condition | Polycystic Ovary Syndrome (PCOS) — a common endocrine disorder affecting over 10% of women worldwide, characterised by hormonal imbalance, metabolic dysfunction, irregular periods, and elevated androgen levels |
|---|---|
| Name Under Review | A decade-long effort to rename PCOS is nearing completion; proposed alternative — “Metabolic Reproductive Syndrome” — better reflects the condition’s hormonal and metabolic nature and avoids implying it is exclusively a female or ovarian disorder |
| Male PCOS Evidence | Brothers and sons of women with PCOS show elevated risk of hyperinsulinaemia, dyslipidaemia, early-onset baldness, obesity, and cardiovascular disease — mirroring the metabolic profile of female PCOS, suggesting shared genetic and hormonal origins |
| Hormonal Difference in Men | Unlike women with PCOS who have excess androgens, men with PCOS susceptibility present with low androgen levels, elevated prolactin, sparse facial and body hair, early-onset male-pattern baldness, and suspected insulin resistance |
| Genetic Risk Findings | Men carrying high genetic risk scores for PCOS face increased likelihood of obesity, type 2 diabetes, and cardiovascular disease — independent of gonadotrophin and sex steroid levels, indicating a metabolic rather than purely reproductive mechanism |
| Prenatal Origin Theory | Women with PCOS have elevated androgen concentrations during pregnancy; their daughters are more likely to develop PCOS, and their sons show early markers of metabolic dysfunction — suggesting fetal androgen exposure programs lifelong health risks for both sexes |
| Animal Study Evidence | Male sheep prenatally exposed to excess androgens developed hyperinsulinaemia, dyslipidaemia, early liver fibrosis, and mitochondrial dysfunction — directly paralleling metabolic findings in sons of human PCOS pregnancies |
| Key Liver Finding (Animal Model) | Over 1,000 genes and 408 proteins were altered in the livers of prenatally androgenised male sheep; cholesterol trafficking was disrupted, with increased hepatic cholesterol accumulation and markers of early non-alcoholic fatty liver disease (NAFLD) |
| Current Diagnostic Gap | PCOS in males has no established clinical name or formal diagnostic pathway; most men with relevant symptoms — metabolic dysfunction, hormonal imbalance, early baldness — are assessed in isolation without the PCOS genetic context being considered |
| Proposed Path Forward | Researchers recommend recognising fetal androgen excess from PCOS pregnancies as a risk factor for poor metabolic health in both sexes; renaming the condition is seen as a necessary first step toward closing the diagnostic and awareness gap for men |
Clinicians and researchers are far less certain. In fact, for over ten years, there has been a persistent effort to rename polycystic ovary syndrome. This effort has been fueled in part by mounting evidence that the condition’s effects extend well beyond the ovaries and beyond women. The name is “incorrect and misleading,” according to a 2023 paper in the journal Fertility and Sterility, which was named after a line from Romeo and Juliet. The authors contend that ovaries do not exhibit cysts but rather arrested follicles, and that the ovarian feature is a nonspecific marker common in younger patients rather than a defining feature of the disorder. According to the authors, the name was actively causing harm by promoting both overdiagnosis based on imaging and underdiagnosis in patients whose presentations didn’t match the expected picture.
“Metabolic Reproductive Syndrome” is a less glamorous but far more accurate substitute. Insulin resistance, dyslipidemia, androgen imbalance, and increased cardiovascular risk are all signs of PCOS, which is fundamentally a disorder of hormonal and metabolic dysregulation. These issues are not specific to women. These are systemic issues that happen to show up in different ways based on the hormonal environment of the body. Androgen levels are elevated in women with PCOS, resulting in symptoms like excess body hair, irregular periods, and problems with fertility. The hormonal picture frequently reverses in men with the genetic susceptibility—lower androgens, elevated prolactin, sparse body hair, early-onset male-pattern baldness—but the underlying metabolic damage is strikingly similar.
It is important to acknowledge that there is still a dearth of research on the sons and brothers of women with PCOS. Few large-scale human studies have been conducted. But what is there is remarkable. Hyperinsulinemia, abnormal lipid levels, obesity, and an increased risk of cardiovascular disease are all more common in men with high genetic risk scores for PCOS. These metabolic alterations seem to function independently of testosterone and other sex hormone levels, indicating that the mechanism is more complex and involves the body’s handling of insulin, cholesterol, and energy metabolism rather than just androgen imbalance. Because women with PCOS have higher androgen concentrations during pregnancy and there is evidence that this hormonal environment programs both their sons and daughters toward poorer metabolic health throughout their lifetimes, some researchers think the origin may be prenatal.
This theory has been pushed in unsettling directions by research on animals. In order to replicate the hormonal conditions of a PCOS pregnancy, male sheep exposed to excess androgens during pregnancy developed hyperinsulinemia, disrupted cholesterol metabolism, early indicators of liver fibrosis, and mitochondrial dysfunction. In their livers, more than 400 proteins and more than a thousand genes were changed. Researchers observed that the hepatic damage was similar to early non-alcoholic fatty liver disease. The sons of women with PCOS may be accumulating metabolic damage for years before any clinician considers linking it to their mother’s endocrine history, if this pattern translates meaningfully to humans and the animal model was specifically chosen for its clinical realism.
Watching this develop is subtly annoying. Early baldness, insulin resistance in a man in his thirties, elevated cholesterol in a teenage boy—all of these conditions are evaluated and treated separately, with no consideration given to whether the hormonal and genetic background of the family may be relevant. Male PCOS simply does not yet have a diagnostic framework, and in clinical practice, the condition is essentially invisible without a name.
It’s still unclear whether a new name will be sufficient to alter how doctors treat male patients with these overlapping symptoms, or how soon the renaming effort will be formally adopted. In medicine, names are very important because they dictate what is coded, what is studied, and who is consulted when something goes wrong. For many years, the term “polycystic ovary syndrome” has informed medical professionals that this is an ovarian issue that affects women. Now, the science is increasingly arguing that the address was never correct.
London Bilingualism's content on health, medicine, and weight loss is solely meant for general educational and informational purposes. This website does not offer any diagnosis, treatment recommendations, or medical advice.
We consistently compile and disseminate the most recent information, findings, and advancements from the medical, health, and weight loss sectors. When content contains opinions, commentary, or viewpoints from professionals, industry leaders, or other people, it is published exactly as it is and reflects those people's opinions rather than London Bilingualism's editorial stance.
We strongly advise all readers to consult a qualified medical professional before acting on any medical, health, dietary, or pharmaceutical information found on this website. Since every person's health situation is different, only a qualified healthcare provider who is familiar with your medical history can offer you advice that is suitable for you.
In a similar vein, any legal, regulatory, or compliance-related information found on this platform is provided solely for informational purposes and should not be used without first obtaining independent legal counsel from a licensed attorney.
You understand and agree that London Bilingualism, its editors, contributors, and affiliated parties are not responsible for any decisions made using the information on this website.
